Angle PLC Announces Change of Adviser
-
Allegations of new cover-up over Epstein files
-
Atletico go third with comfortable win at Girona
-
Schwarz breaks World Cup duck with Alta Badia giant slalom victory
-
Salah unaffected by Liverpool turmoil ahead of AFCON opener - Egypt coach
-
Goggia eases her pain with World Cup super-G win as Vonn takes third
-
Goggia wins World Cup super-G as Vonn takes third
-
Cambodia says Thai border clashes displace over half a million
-
Kremlin denies three-way US-Ukraine-Russia talks in preparation
-
Williamson says 'series by series' call on New Zealand Test future
-
Taiwan police rule out 'terrorism' in metro stabbing
-
Australia falls silent, lights candles for Bondi Beach shooting victims
-
DR Congo's amputees bear scars of years of conflict
-
Venison butts beef off menus at UK venues
-
Cummins, Lyon doubts for Melbourne after 'hugely satsfying' Ashes
-
'It sucks': Stokes vows England will bounce back after losing Ashes
-
Australia probes security services after Bondi Beach attack
-
West Indies need 462 to win after Conway's historic century
-
Thai border clashes displace over half a million in Cambodia
-
Australia beat England by 82 runs to win third Test and retain Ashes
-
China's rare earths El Dorado gives strategic edge
-
Japan footballer 'King Kazu' to play on at the age of 58
-
New Zealand's Conway joins elite club with century, double ton in same Test
-
Australian PM orders police, intelligence review after Bondi attack
-
Durant shines as Rockets avenge Nuggets loss
-
Pressure on Morocco to deliver as Africa Cup of Nations kicks off
-
Australia remove Smith as England still need 126 to keep Ashes alive
-
Myanmar mystics divine future after ill-augured election
-
From the Andes to Darfur: Colombians lured to Sudan's killing fields
-
Eagles win division as Commanders clash descends into brawl
-
US again seizes oil tanker off coast of Venezuela
-
New Zealand 35-0, lead by 190, after racing through West Indies tail
-
How Can Gum Disease Lead to Tooth Loss in Kyle, TX?
-
West Indies 420 all out to trail New Zealand by 155
-
Arteta tells leaders Arsenal to 'learn' while winning
-
Honour to match idol Ronaldo's Real Madrid calendar year goal record: Mbappe
-
Dupont helps Toulouse bounce back in Top 14 after turbulent week
-
Mbappe matches Ronaldo record as Real Madrid beat Sevilla
-
Gyokeres ends drought to gift Arsenal top spot for Christmas
-
Arsenal stay top despite Man City win, Liverpool beat nine-man Spurs
-
US intercepts oil tanker off coast of Venezuela
-
PSG cruise past fifth-tier Fontenay in French Cup
-
Isak injury leaves Slot counting cost of Liverpool win at Spurs
-
Juve beat Roma to close in on Serie A leaders Inter
-
US intercepts oil tanker off coast of Venezuela: US media
-
Haaland sends Man City top, Liverpool beat nine-man Spurs
-
Epstein victims, lawmakers criticize partial release and redactions
-
Leverkusen beat Leipzig to move third in Bundesliga
-
Lakers guard Smart fined $35,000 for swearing at refs
-
Liverpool sink nine-man Spurs but Isak limps off after rare goal
-
Guardiola urges Man City to 'improve' after dispatching West Ham
NYSE - LSE
Angle PLC Announces Change of Adviser
APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER
APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER
GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has appointed Cavendish Capital Markets Limited as the Company's Nominated Adviser and Sole Broker with immediate effect.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Cavendish (NOMAD and Broker) | +44 (0) 20 7220 0500 |
FTI Consulting |
|
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 115 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
